USPTO serial 79369882
N NUAGE THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 30, 2024
- Examiner
- BHANOT, KAPIL KUMAR
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with N NUAGE THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lawrence Apolzon
Lawrence Apolzon Fross Zelnick Lehrman & Zissu, P.C.151 W 42nd Street, 17th FloorNew York, NY 10036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in product development in the fields of science, scientific research and for laboratory use; in vitro analytical and diagnostic reagents for scientific use | ACTIVE | — |
| 005 | Pharmaceutical preparations for targeting of disordered proteins; chemical, analytical and diagnostic reagents for in vitro medical or veterinary use; chemical reagents for medical use; chemical reagents for use in medical or veterinary diagnostics; pharmaceutical preparations for use in the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of ophthalmic diseases and conditions and for the treatment of inflammation and inflammatory conditions and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical products for the prevention and treatment of immune-related, neurological and neurodegenerative diseases | ACTIVE | — |
| 040 | Custom manufacture of cell lines for use in the manufacture of biopharmaceutical products; custom manufacture of proteins for third parties; custom manufacture of medicines; custom manufacture of biopharmaceuticals | ACTIVE | — |
| 042 | Scientific, medical, and medical industrial research and development services; medical clinical research studies; laboratory medical research; research and development of new drugs and medical clinical products; analysis of materials; chemical analysis; medical and scientific laboratory services; laboratory medical testing services; medical laboratory services; information and advisory services relating to the aforesaid, including such services provided online from a computer network or via the internet; research and development services for pharmaceutical preparations and for the treatment of diseases and injuries; genetic engineering services; genetic research for scientific or medical purposes; scientific research and development; scientific research in the field of genetics; medical and pharmacological research services; research and development in the fields of biotechnology, biopharmaceuticals, and gene therapies; medical and scientific research, namely conducting clinical trials; research and development of pharmaceutical products; research and development of vaccines and medicines; stem cell research; research and development in the fields of microorganisms and cells; research in the field of gene therapies; advisory services relating to gene therapy research; biological research, clinical medical research and medical research; product development; biological product development services; consultancy relating to pharmaceutical research and development; providing scientific information in the field of medical disorders and their treatment; pharmaceutical research and development; scientific services relating to the isolation and cultivation of human tissues and cells; research related to molecular science; analysis in the field of molecular biology; research services relating to molecular sciences | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Nuage Therapeutics, S.L.
- Other trademarks owned by Nuage Therapeutics, S.L.
- Other trademarks owned by Nuage Therapeutics, S.L.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named N NUAGE THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 15, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 27, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 27, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 30, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 30, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 30, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 14, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 14, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 24, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 5, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 28, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 27, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 27, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 17, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 27, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 27, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 9, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 8, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 6, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| May 26, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 22, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 18, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |